Neurocrine announces Phase I/II glioma results

NBIX said 56 percent of 29 evaluable patients had a >50 percent reduction in tumor size in its 31-patient U.S. and German Phase I/II trial to treat advanced malignant glioma. The study tested NBIX's I...